<DOC>
	<DOCNO>NCT00398047</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , azacitidine , work different way stop growth abnormal cell , either kill cell stop divide . Colony-stimulating factor , darbepoetin alfa G-CSF , may increase number red blood cell white blood cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Giving azacitidine together darbepoetin alfa G-CSF may effective treatment myelodysplastic syndrome . PURPOSE : This clinical trial study well give azacitidine together darbepoetin alfa G-CSF work treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Azacitidine , Darbepoetin Alfa , Erythropoietin Filgastrim ( G-CSF ) Treating Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine hematological response rate patient myelodysplastic syndrome treat azacitidine , darbepoetin alfa , filgrastim ( G-CSF ) . Secondary - Determine time leukemia progression , survival , change apoptotic index bone marrow patient treat regimen . OUTLINE : This open-label , nonrandomized study . - Initial therapy ( course 1 2 ) : Patients receive azacitidine subcutaneously ( SC ) intra-venous ( IV ) day 1-5 ( week 1 ) darbepoetin alfa* SC day 8 ( week 2 ) . Treatment repeat every 28 day 2 course . Patients undergo bone marrow aspirate biopsy ass response . Patients major hematological improvement OR grade 3-4 hematological toxicity first 2 course therapy AND/OR ≥ 50 % reduction bone marrow cellularity compare baseline proceed optimization therapy A . Patients meet criterion proceed optimization therapy B . Patients disease progression remove study . - Optimization therapy A ( course 3-8 ) : Patients receive azacitidine SC IV day 1-5 ( week 1 ) , darbepoetin alfa** SC day 8 ( week 2 ) , filgrastim ( G-CSF ) SC 3 time weekly week 2-4 . - Optimization therapy B ( course 3-8 ) : Patients receive high dose azacitidine day 1-5 ( week 1 ) , darbepoetin alfa** SC day 8 ( week 2 ) , G-CSF 3 time weekly week 2-4 . In optimization therapy A B , treatment repeat every 28 day 6 course . Patients degree hematological improvement initial therapy optimization therapy proceed maintenance therapy . - Maintenance therapy ( course 9 subsequent course ) : Patients receive azacitidine day 1-5 ( week 1 ) . Only patient anemia ( hemoglobin &lt; 12 g/dL ) and/or neutropenia ( absolute neutrophil count &lt; 1,500/mm ³ ) start give course maintenance therapy receive darbepoetin alfa** SC begin day 8 ( week 2 ) continue every 21 day G-CSF SC 3 time weekly begin week 2 . Courses repeat every 28-56 day ( determined treat physician ) absence disease progression unacceptable toxicity . Bone marrow sample obtain baseline completion course 2 study treatment apoptosis analysis , flow cytometry , gene expression profile p53 p21 immunohistochemistry . Peripheral blood sample obtain periodically analyze hemoglobin F quantitation . NOTE : *Administered patient anemic ( hemoglobin &lt; 12 g/dL ) . NOTE : **Darbepoetin alfa hold hemoglobin &gt; 12 g/dL day 1 give cycle .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis myelodysplastic syndrome ( MDS ) Bone marrow aspirate biopsy karyotyping perform within past 8 week Patients chronic myelomonocytic leukemia ( CMML ) , refractory anemia ( RA ) , refractory anemia ring sideroblast ( RARS ) accord FAB classification OR RA , RARS , refractory anemia multilineage dysplasia , RARS multilineage dysplasia accord WHO classification must meet ≥ 1 follow criterion : Symptomatic anemia require RBC transfusion ≥ 3 month study entry Thrombocytopenia ≥ 2 platelet count &lt; 50,000/mm³ OR significant hemorrhage require platelet transfusion Neutropenia absolute neutrophil count &lt; 1,000/mm³ infection require IV antibiotic No refractory anemia excess blast transformation No history leukemia No known primary metastatic hepatic tumor PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 2 month AST ALT ≤ 2 time upper limit normal Creatinine &lt; 2.0 mg/dL Serum vitamin B12 normal Serum and/or red cell folate level normal Ferritin ≥ 50 ng/mL Copper &gt; 40 µg/dL Not pregnant nursing Fertile patient must use effective contraception Negative pregnancy test PRIOR CONCURRENT THERAPY : No prior azacitidine decitabine No prior therapy MDS Supportive therapy within past 28 day allow No concurrent treatment MDS ( i.e. , thalidomide , arsenic trioxide , cyclosporine , melphalan ) No concurrent hematopoietic growth factor , include epoetin alfa , filgrastim ( GCSF ) , sargramostim ( GMCSF ) , interleukin11 ( oprelvekin )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>